KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Non-Current Assets: 2009-2025

Historic Non-Current Assets for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $892.5 million.

  • Halozyme Therapeutics' Non-Current Assets fell 9.95% to $892.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $892.5 million, marking a year-over-year decrease of 9.95%. This contributed to the annual value of $978.1 million for FY2024, which is 0.88% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Non-Current Assets stood at $892.5 million for Q3 2025, which was down 4.16% from $931.2 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Non-Current Assets high stood at $1.2 billion for Q2 2022, and its period low was $24.9 million during Q1 2021.
  • Its 3-year average for Non-Current Assets is $982.4 million, with a median of $981.7 million in 2024.
  • Per our database at Business Quant, Halozyme Therapeutics' Non-Current Assets surged by 4,646.49% in 2022 and then fell by 16.32% in 2023.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Non-Current Assets stood at $178.1 million in 2021, then skyrocketed by 518.89% to $1.1 billion in 2022, then dropped by 10.49% to $986.8 million in 2023, then fell by 0.88% to $978.1 million in 2024, then fell by 9.95% to $892.5 million in 2025.
  • Its Non-Current Assets stands at $892.5 million for Q3 2025, versus $931.2 million for Q2 2025 and $934.5 million for Q1 2025.